Ottobock SE & Co. KGaA
ISIN: DE000BCK2223
WKN: BCK222
19 Juni 2026 11:30AM

EQS-News: Ottobock sells its Human Mobility wheelchair business

Ottobock SE & Co. KGaA · ISIN: DE000BCK2223 · EQS - Company News
Land: Deutschland · Primärmarkt: Deutschland · EQS News ID: 2349470

EQS-News: Ottobock SE & Co. KGaA / Key word(s): Disposal/Strategic Company Decision
Ottobock sells its Human Mobility wheelchair business

19.06.2026 / 11:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Ottobock sells its Human Mobility wheelchair business

Ottobock sharpens its strategic focus on its core business / DHCare invests in the expansion of its European business

Duderstadt, June 19, 2026
 

Publicly listed global MedTech company Ottobock SE & Co. KGaA signed an agreement on June 19, 2026 to sell its Human Mobility business unit to the international medical technology company DHCare. The transaction is expected to close in H2/2026.

With the sale, Ottobock is consistently continuing its strategic focus on its core business. In the future, the company will concentrate even more strongly on the areas where it sees the greatest growth potential, particularly prosthetics and neuro-orthotics.

Oliver Jakobi, CEO of Ottobock SE & Co. KGaA, said: “By selling our wheelchair business, we are sharpening our strategic focus on our core business. At the same time, with DHCare we have found the right investor for Human Mobility. The team has built a technologically leading business with strong clinical credibility and close customer relationships. We are convinced that Human Mobility has the best opportunities for growth in its new environment.”

A strategic step with a clear perspective

With DHCare, Human Mobility gains a new owner with a broad European footprint and a complementary portfolio. Human Mobility contributes, above all, its strong position in the DACH region and its expertise in complex powered wheelchairs.

Graham Ewart, CEO of DHCare, said: “This acquisition is an important milestone for DHCare. It is our first under the new ownership structure and our first as a combined platform. With Ottobock Human Mobility, we are taking another significant step in expanding our position as a leading provider of mobility solutions in Europe — with high-quality, clinically proven solutions as well as technical support and high-level after-sales service.”

Secured transition for employees and market partners

As part of the transaction, the German Human Mobility companies as well as Dutch pediatric wheelchair specialist veldink4Kids will transfer in full to the new group.

For users, payers, service providers and specialist retailers alike, Ottobock will remain a reliable partner until the transaction is completed.

Dr. Arne Kreitz, CFO of Ottobock SE & Co. KGaA, said: “By divesting this non-core business area, we are continuing to sharpen our focus on expanding high-growth and highly innovative businesses. At the same time, it is important to us to ensure an orderly and reliable transition for the employees and locations affected, as well as for customers and partners. In DHCare, we have found a partner that wants to further develop Human Mobility within a strong European mobility environment.”

Note: In connection with this transaction, the French subsidiaries of both groups have entered into exclusive negotiations for the sale of the French Human Mobility business, and the relevant employee information and consultation processes will be initiated shortly.
 

Media Contact:

Ottobock SE & Co. KGaA
Merle Florstedt
Head of Corporate Communications
Mobile +49 151 441 616 25
Merle.florstedt@ottobock.de 

 

Investor Relations Contact:

Ottobock SE & Co. KGaA
Julia Hartmann
VP Investor Relations
Mobile: +49 151 556 848 07
Julia.Hartmann@ottobock.de

 

About Ottobock

Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with around 420 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988. 

 

About DHCare

DHCare is a global medical device company that supports efforts to move health forward by delivering innovative and leading solutions for individuals whose lives are impacted by reduced movement.

We strive to constantly support our healthcare partners, and the people whose healthcare needs they serve, working to keep improving the vital connections between movement and health, enabling accelerated recovery and healthy independence in daily living.

 



19.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Ottobock SE & Co. KGaA
Max-Näder-Straße 15
37115 Duderstadt
Germany
Phone: +49 5527 848 - 0
E-mail: info@ottobock.com
Internet: https://corporate.ottobock.com
ISIN: DE000BCK2223
WKN: BCK222
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange
EQS News ID: 2349470

 
End of News EQS News Service

2349470  19.06.2026 CET/CEST

Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL. 

Die wichtigsten Finanzdaten auf einen Blick
  2020 2021 2022 2023 2024 2025 2026e
Umsatzerlöse1 0,00 1.187,51 1.333,19 1.495,04 1.604,60 1.679,80 1.790,00
EBITDA1,2 0,00 162,12 1.963,35 248,70 299,20 371,80 440,00
EBITDA-Marge3 0,00 0,00 14,85 16,64 18,65 22,13 24,58
EBIT1,4 0,00 0,00 -934,00 -27,00 290,00 0,00 256,00
EBIT-Marge5 0,00 0,00 0,00 -1,81 18,07 11,07 14,30
Jahresüberschuss1 0,00 19,63 75,33 48,10 27,90 88,30 140,00
Netto-Marge6 0,00 0,00 5,64 3,22 1,74 5,26 7,82
Cashflow1,7 0,00 0,00 82,00 197,80 275,10 333,20 0,00
Ergebnis je Aktie8 0,00 0,00 1,17 0,75 0,44 1,44 2,10
Dividende8 0,00 0,00 0,00 0,00 0,00 0,97 1,05
Quelle: boersengefluester.de und Firmenangaben
Legende

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.

INVESTOR-INFORMATIONEN
©boersengefluester.de
Ottobock
WKN ISIN Rechtsform Börsenwert IPO Einschätzung Plus Code
BCK222 DE000BCK2223 SE & Co. KGaA 3.218,71 Mio € 09.10.2025 9F3GG68Q+78
* * *
KGV 2027e KGV 10Y-Ø BGFL-Ratio Shiller-KGV KBV KCV KUV
20,96 23,95 0,88 38,69 9,81 9,66 1,92
Dividenden
Dividende '2023
in €
Dividende '2024
in €
Dividende '2025e
in €
Div.-Rendite '2025e
in %
0,00 0,00 0,97 1,93%
Finanztermine
Hauptversammlung Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
19.05.2026 06.05.2026 13.08.2026 12.11.2026 19.03.2026
Performance-Angaben
Abstand 60-Tage-Linie Abstand 200-Tage-Linie Performance YtD Kursveränderung 52 Wochen IPO
Akt. Kurs (EoD)
-2,33%
50,30 €
ATH 76,35 €
-9,48% +0,00% -22,91% +0,00% -23,79%

Werbung ist für uns ein wichtiger Einnahmekanal. Aber wir verstehen, dass sie manchmal lästig wird. Wenn Sie die Anzahl der angezeigten Werbung reduzieren möchten, loggen Sie sich einfach in Ihr Benutzerkonto ein und verwalten Sie die Einstellungen von dort aus. Als registrierter Benutzer erhalten Sie viele Vorteile.
          Qualitätsjournalismus · 2013-2026 · Made in Germany          
Die Analyse-Manufaktur

Informierte Anleger treffen bessere Entscheidungen

Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.

Kontakt

Idee & Konzept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 von Gereon Kruse #BGFL